EOLS News and Press, Evolus Inc. From 03/07/24

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-03-06 17:20:04 ET More on Evolus Evolus: Negative Earnings Continue Despite Sustained Top-Line Growth Evolus, Alvotech gain as Barclays raises to Ovrweight Evolus shares rise on upbeat 2024 revenue outlook Seeking Alpha’s Quant Rating on Evolus ...

2024-03-01 14:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Evolus dermal filler product (Evolysse ™ /Estyme ® Lift) demonstrates statistical superiority at 3 and 6 months compared to Restylane-L with respect to improvement in nasolabial fold severity The European Lift study met the primary endpoint of non-inferiority ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tu...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. finan...

2024-02-09 01:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-29 13:28:50 ET More on Alvotech, Evolus, etc. Evolus: Negative Earnings Continue Despite Sustained Top-Line Growth Alvotech: Biosimilars Portfolio Opportunity Is High Risk Alvotech (ALVO) Q3 2023 Earnings Call Transcript Alvotech stock jumps 15% on St...

2024-01-29 04:15:01 ET Barclays analyst issues OVERWEIGHT recommendation for EOLS on January 29, 2024 03:32AM ET. EOLS was trading at $11.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...

2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group  ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus,  ( EOLS ) +2% . SSR Mining  ( SSRM ) +2% . Losers: Progress Software ...